ARSENIC TRIOXIDE injection, solution

ARSENIC TRIOXIDE by

Drug Labeling and Warnings

ARSENIC TRIOXIDE by is a Prescription medication manufactured, distributed, or labeled by Orbicular Pharmaceutical Technologies Private Limited, MSN Laboratories Private Limited. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • BOXED WARNING (What is this?)

    WARNING: DIFFERENTIATION SYNDROME, CARDIAC CONDUCTION ABNORMALITIES AND ENCEPHALOPATHY INCLUDING WERNICKES

    Differentiation Syndrome: Patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide have experienced differentiation syndrome, which may be life-threatening or fatal. Signs and symptoms may include unexplained fever, dyspnea, hypoxia, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusions, weight gain, peripheral edema, hypotension, renal insufficiency, hepatopathy, and multi-organ dysfunction, in the presence or absence of leukocytosis. If differentiation syndrome is suspected, immediately initiate high-dose corticosteroids and hemodynamic monitoring until resolution. Temporarily withhold arsenic trioxide [see Dosage and Administration (2.3), Warnings and Precautions (5.1)].

    Cardiac Conduction Abnormalities: Arsenic trioxide can cause QTc interval prolongation, complete atrioventricular block and torsade de pointes, which can be fatal. Before administering arsenic trioxide, assess the QTc interval, correct electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval. Do not administer arsenic trioxide to patients with a ventricular arrhythmia or prolonged QTc interval. Withhold arsenic trioxide until resolution and resume at reduced dose for QTc prolongation [see Dosage and Administration (2.3), Warnings and Precautions (5.2)].

    Encephalopathy: Serious encephalopathy, including Wernicke's, has occurred with arsenic trioxide. Wernicke's is a neurologic emergency. Consider testing thiamine levels in patients at risk for thiamine deficiency. Administer parenteral thiamine in patients with or at risk for thiamine deficiency. Monitor patients for neurological symptoms and nutritional status while receiving arsenic trioxide. If Wernicke's encephalopathy is suspected, immediately interrupt arsenic trioxide and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize [see Warnings and Precautions (5.3)].

  • 1 INDICATIONS AND USAGE

    1.2 Relapsed or Refractory APL

    Arsenic trioxide injection is indicated for induction of remission and consolidation in patients with APL who are refractory to, or have relapsed from, retinoid and anthracycline chemotherapy, and whose APL is characterized by the presence of the t(15;17) translocation or PML/RAR-alpha gene expression.

  • 2 DOSAGE AND ADMINISTRATION

    2.2 Recommended Dosage for Relapsed or Refractory APL

    A treatment course for patients with relapsed or refractory APL consists of 1 induction cycle and 1 consolidation cycle [see Clinical Studies (14.2)].

    • For the induction cycle, the recommended dosage of arsenic trioxide injection is 0.15 mg/kg/day intravenously daily until bone marrow remission or up to a maximum of 60 days.
    • For the consolidation cycle, the recommended dosage of arsenic trioxide injection is 0.15 mg/kg/day intravenously daily for 25 doses over a period of up to 5 weeks. Begin consolidation 3 to 6 weeks after completion of induction cycle.

    2.3 Monitoring and Dosage Modifications for Adverse Reactions

    During induction, monitor coagulation studies, blood counts, and chemistries at least 2 to 3 times per week through recovery. During consolidation, monitor coagulation studies, blood counts, and chemistries at least weekly.

    Table 2 shows the dosage modifications for adverse reactions due to arsenic trioxide injection when used alone.

    Table 2: Dosage Modifications for Adverse Reactionsof Arsenic Trioxide Injection
    Adverse Reaction
    		Dosage Modification
    Differentiation syndrome, defined by the presence of 2 or more of the following:
    -    Unexplained fever
    -    Dyspnea
    -    Pleural and/or pericardial effusion
    -    Pulmonary infiltrates
    -    Renal failure
    -    Hypotension
    -    Weight gain greater than 5 kg
    [see Warnings and Precautions (5.1)]
    • Temporarily withhold arsenic trioxide injection.
    • Administer dexamethasone 10 mg intravenously every 12 hours until the resolution of signs and symptoms for a minimum of 3 days.
    • Resume treatment when the clinical condition improves and reduce the dose of the withheld drug(s) by 50%.
    • Increase the dose of the withheld drug(s) to the recommended dosage after one week in the absence of recurrence of symptoms of differentiation syndrome.
    • If symptoms re-appear, decrease arsenic trioxide injection to the previous dose.
    QTc (Framingham formula) Prolongation greater than 450 msec for men or greater than 460 msec for women [see Warnings and Precautions (5.2)]
     
    • Withhold arsenic trioxide injection and any medication known to prolong the QTc interval.
    • Correct electrolyte abnormalities.
    • After the QTc normalizes and electrolyte abnormalities are corrected, resume treatment with arsenic trioxide injection at a 50% reduced dose (0.075 mg/kg/day daily) for one week after resolution.
    • If the 50% reduced dose is tolerated for one week (in the absence of QTc prolongation), increase the dose of arsenic trioxide injection to 0.11 mg/kg/day daily for the next week.
    • The dose of arsenic trioxide injection can be increased to 0.15 mg/kg/day in the absence of QTc prolongation during that 14-day dose-escalation period.
    Hepatotoxicity, defined by 1 or more of the following:
    -    Total bilirubin (TB) greater than 3 times the upper limit of normal (ULN)
    -    Aspartate aminotransferase (AST) greater than 5 times the ULN
    -    Alkaline phosphatase (AP) greater than 5 times the ULN
    [see Warnings and Precautions (5.4)]
    • Withhold arsenic trioxide injection.
    • Resume treatment at a 50% reduced dose of the withheld drug(s) when TB is less than 1.5 times the ULN and AP/AST are less than 3 times the ULN.
    • Increase the dose of the withheld drug back to the recommended dosage after one week on the reduced dose in the absence of worsening of hepatotoxicity.
    • Discontinue the withheld drug permanently if hepatotoxicity recurs.
    Other severe or life-threatening (grade 3 to 4) nonhematologic reactions
    [see Adverse Reactions (6)]
    • Temporarily withhold arsenic trioxide injection.
    • When the adverse reaction resolves to no more than mild (grade 1), resume arsenic trioxide injection reduced by 2 dose levels (see Table 3 below).
    Moderate (grade 2) nonhematologic reactions
    [see Adverse Reactions (6)]
    • Reduce the dose of arsenic trioxide injection by 1 dose level (see Table 3 below).
    Leukocytosis (WBC count greater than 10 Gi/L)
    [see Adverse Reactions (6.1)]
    • Administer hydroxyurea.
    • Hydroxyurea may be discontinued when the WBC declines below 10 Gi/L.
    Myelosuppression, defined by 1 or more of the following:
    -    absolute neutrophil count less than 1 Gi/L. 
    -    Platelets less than 50 Gi/L lasting more than 5 weeks
    [see Adverse Reactions (6)]
    • Consider reducing the dose of arsenic trioxide injection by 1 dose level (see Table 3 below).
    • If myelosuppression lasts ≥ 50 days or occurs on 2 consecutive cycles, assess a marrow aspirate for remission status. In the case of molecular remission, resume arsenic trioxide injection at 1 dose level lower (see Table 3 below).
    Table 3: Dose Reduction Levels for Hematologic and Nonhematologic Toxicities
    Dose Level
    		Arsenic Trioxide Injection
    mg/kg intravenously
    once daily
    Starting level
    		 0.15
    -1
    		 0.11
    -2
    		 0.10
    -3
    		 0.075

    2.4 Preparation and Administration

    Reconstitution

    Dilute arsenic trioxide injection with 100 mL to 250 mL 5% Dextrose Injection, USP or 0.9% Sodium Chloride Injection, USP, using proper aseptic technique, immediately after withdrawal from the vial. Do not save any unused portions for later administration.

    After dilution, store arsenic trioxide injection for no more than 24 hours at room temperature and 48 hours when refrigerated.

    Administration

    Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit.

    Administer arsenic trioxide injection as an intravenous infusion over 2 hours. The infusion duration may be extended up to 4 hours if acute vasomotor reactions are observed. A central venous catheter is not required.

    The arsenic trioxide injection vial is single-dose and does not contain any preservatives. Discard unused portions of each vial properly. Do not mix arsenic trioxide injection with other medications.

    Safe Handling Procedures

    Arsenic trioxide injection is a hazardous drug. Follow applicable special handling and disposal procedures.1

  • 3 DOSAGE FORMS AND STRENGTHS

    Injection: 10 mg/10 mL (1 mg/mL) arsenic trioxide clear solution in a single-dose vial.

    Injection: 12 mg/6 mL (2 mg/mL) arsenic trioxide clear solution in a single-dose vial.

  • 4 CONTRAINDICATIONS

    Arsenic trioxide injection is contraindicated in patients with hypersensitivity to arsenic.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 Differentiation Syndrome

    Differentiation syndrome, which may be life-threatening or fatal, has been observed in patients with acute promyelocytic leukemia (APL) treated with arsenic trioxide. In clinical trials, 16% to 23% of patients treated with arsenic trioxide for APL developed differentiation syndrome. Signs and symptoms include unexplained fever, dyspnea, hypoxia, acute respiratory distress, pulmonary infiltrates, pleural or pericardial effusion, weight gain, peripheral edema, hypotension, renal insufficiency, hepatopathy and multi-organ dysfunction. Differentiation syndrome has been observed with and without concomitant leukocytosis, and it has occurred as early as day 1 of induction to as late as the second month induction therapy.

    If differentiation syndrome is suspected, temporarily withhold arsenic trioxide and immediately initiate dexamethasone 10 mg intravenously every 12 hours and hemodynamic monitoring until resolution of signs and symptoms for a minimum of 3 days [see Dosage and Administration (2.3)].

    5.2 Cardiac Conduction Abnormalities

    Patients treated with arsenic trioxide can develop QTc prolongation, torsade de pointes, and complete atrioventricular block. In the clinical trial of patients with relapsed or refractory APL treated with arsenic trioxide monotherapy, 40% had at least one ECG tracing with a QTc interval greater than 500 msec. A prolonged QTc was observed between 1 and 5 weeks after start of arsenic trioxide infusion, and it usually resolved by 8 weeks after arsenic trioxide infusion. There are no data on the effect of arsenic trioxide on the QTc interval during the infusion of the drug.

    The risk of torsade de pointes is related to the extent of QTc prolongation, concomitant administration of QTc prolonging drugs, a history of torsade de pointes, pre-existing QTc interval prolongation, congestive heart failure, administration of potassium-wasting diuretics, or other conditions that result in hypokalemia or hypomagnesemia. The risk may be increased when arsenic trioxide is co-administered with medications that can lead to electrolyte abnormalities (such as diuretics or amphotericin B) [see Drug Interactions (7)].

    Prior to initiating therapy with arsenic trioxide, assess the QTc interval by electrocardiogram, correct pre-existing electrolyte abnormalities, and consider discontinuing drugs known to prolong QTc interval. Do not administer arsenic trioxide to patients with a ventricular arrhythmia or prolonged QTc. If possible, discontinue drugs that are known to prolong the QTc interval. If it is not possible to discontinue the interacting drug, perform cardiac monitoring frequently [see Drug Interactions (7)]. During arsenic trioxide therapy, maintain potassium concentrations above 4 mEq/L and magnesium concentrations above 1.8 mg/dL. Monitor ECG weekly and more frequently for clinically unstable patients.

    For patients who develop a QTc Framingham greater than 450 msec for men or greater than 460 msec for women, withhold arsenic trioxide and any medication known to prolong the QTc interval. Correct electrolyte abnormalities. When the QTc normalizes and electrolyte abnormalities are corrected, resume arsenic trioxide at a reduced dose [see Dosage and Administration (2.3)].

    5.3 Encephalopathy

    Serious encephalopathies were reported in patients receiving arsenic trioxide. Monitor patients for neurological symptoms, such as confusion, decreased level of consciousness, seizures, cognitive deficits, ataxia, visual symptoms and ocular motor dysfunction. Advise patients and caregivers of the need for close observation.

    Wernicke's Encephalopathy

    Wernicke's encephalopathy occurred in patients receiving arsenic trioxide. Wernicke's encephalopathy is a neurologic emergency that can be prevented and treated with thiamine. Consider testing thiamine levels in patients at risk for thiamine deficiency (e.g., chronic alcohol use, malabsorption, nutritional deficiency, concomitant use of furosemide). Administer parenteral thiamine in patients with or at risk for thiamine deficiency. Monitor patients for neurological symptoms and nutritional status while receiving arsenic trioxide. If Wernicke's encephalopathy is suspected, immediately interrupt arsenic trioxide and initiate parenteral thiamine. Monitor until symptoms resolve or improve and thiamine levels normalize.

    5.4 Hepatotoxicity

    Long-term liver abnormalities can occur in patients with APL treated with arsenic trioxide.

    During treatment with arsenic trioxide, monitor hepatic function tests at least twice weekly during induction and at least once weekly during consolidation. Withhold arsenic trioxide if elevations in AST or alkaline phosphatase occur to greater than 5 times the upper limit of normal and/or elevation in serum total bilirubin occurs to greater than 3 times the upper limit of normal and resume at reduced dose upon resolution [see Dosage and Administration (2.3)].

    5.5 Carcinogenesis

    The active ingredient of arsenic trioxide injection, arsenic trioxide, is a human carcinogen. Monitor patients for the development of second primary malignancies.

    5.6 Embryo-Fetal Toxicity

    Arsenic trioxide can cause fetal harm when administered to a pregnant woman. Arsenic trioxide was embryolethal and teratogenic in rats when administered on gestation day 9 at a dose approximately 10 times the recommended human daily dose on a mg/m2 basis. A related trivalent arsenic, sodium arsenite, produced teratogenicity when administered during gestation in mice at a dose approximately 5 times the projected human dose on a mg/m2 basis and in hamsters at an intravenous dose approximately equivalent to the projected human daily dose on a mg/m2 basis.

    Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with arsenic trioxide and for 6 months after the last dose. Advise males with female partners of reproductive potential to use effective contraception during treatment with arsenic trioxide and for 3 months after the last dose [see Use in Specific Populations (8.1, 8.3)].

  • 6 ADVERSE REACTIONS

    The following clinically significant adverse reactions are described elsewhere in the labeling:

    • Differentiation Syndrome [see Warnings and Precautions (5.1)]
    • Cardiac Conduction Abnormalities [see Warnings and Precautions (5.2)]
    • Encephalopathy [see Warnings and Precautions (5.3)]
    • Hepatotoxicity [see Warnings and Precautions (5.4)]
    • Carcinogenesis [see Warnings and Precautions (5.5)]

    6.1 Clinical Trials Experience

    Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

    Relapsed or Refractory APL

    Safety information was available for 52 patients with relapsed or refractory APL who participated in clinical trials of arsenic trioxide. Forty patients in the Study PLRXAS01 received the recommended dose of 0.15 mg/kg, of whom 28 completed both induction and consolidation cycles. An additional 12 patients with relapsed or refractory APL received doses generally similar to the recommended dose.

    Serious adverse reactions observed in the 40 patients with refractory or relapsed APL enrolled in Study PLRXAS01 included differentiation syndrome (n=3), hyperleukocytosis (n=3), QTc interval ≥ 500 msec (n=16, 1 with torsade de pointes), atrial dysrhythmias (n=2), and hyperglycemia (n=2).

    The most common adverse reactions (> 30%) were nausea, cough, fatigue, pyrexia, headache, abdominal pain, vomiting, tachycardia, diarrhea, dyspnea, hypokalemia, leukocytosis, hyperglycemia, hypomagnesemia, insomnia, dermatitis, edema, QTc prolongation, rigors, sore throat, arthralgia, paresthesia, and pruritus.

    Table 5 describes the adverse reactions in patients aged 5 to 73 years with APL who received arsenic trioxide at the recommended dose. Similar adverse reactions profiles were seen in the other patient populations who received arsenic trioxide.

    Table 5: Adverse Reactions (≥ 5%) in Patients with Relapsed or Refractory APL Who Received Arsenic Trioxide in Study PLRXAS01
    Body System
    Adverse reaction
    		 Any Grade
    Adverse Reactions
    		Grade ≥3
    Adverse Reactions
    n
    		%
    		n
    		%
    Gastrointestinal disorders
    Nausea
    		 30
    		 75
    Abdominal pain (lower & upper)
    		 23
    		 58
    		 4
    		 10
    Vomiting
    		 23
    		 58
    Diarrhea
    		 21
    		 53
    Sore throat
    		 14
    		 35
    Constipation
    		 11
    		 28
    		 1
    		 3
    Anorexia
    		 9
    		 23
    Appetite decreased
    		 6
    		 15
    Loose stools
    		 4
    		 10
    Dyspepsia
    		 4
    		 10
    Oral blistering
    		 3
    		 8
    Fecal incontinence
    		 3
    		 8
    Gastrointestinal hemorrhage
    		 3
    		 8
    Dry mouth
    		 3
    		 8
    Abdominal tenderness
    		 3
    		 8
    Diarrhea hemorrhagic
    		 3
    		 8
    Abdominal distension
    		 3
    		 8
    Respiratory
    Cough
    		 26
    		 65
    Dyspnea
    		 21
    		 53
    		 4
    		 10
    Epistaxis
    		 10
    		 25
    Hypoxia
    		 9
    		 23
    		 4
    		 10
    Pleural effusion
    		 8
    		 20
    		 1
    		 3
    Post nasal drip
    		 5
    		 13
    Wheezing
    		 5
    		 13
    Decreased breath sounds
    		 4
    		 10
    Crepitations
    		 4
    		 10
    Rales
    		 4
    		 10
    Hemoptysis
    		 3
    		 8
    Tachypnea
    		 3
    		 8
    Rhonchi
    		 3
    		 8
    General disorders and administration site conditions
    Fatigue
    		 25
    		 63
    		 2
    		 5
    Pyrexia (fever)
    		 25
    		 63
    		 2
    		 5
    Edema - non-specific
    		 16
    		 40
    Rigors
    		 15
    		 38
    Chest pain
    		 10
    		 25
    		 2
    		 5
    Injection site pain
    		 8
    		 20
    Pain - non-specific
    		 6
    		 15
    		 1
    		 3
    Injection site erythema
    		 5
    		 13
    Weight gain
    		 5
    		 13
    Injection site edema
    		 4
    		 10
    Weakness
    		 4
    		 10
    		 2
    		 5
    Hemorrhage
    		 3
    		 8
    Weight loss
    		 3
    		 8
    Drug hypersensitivity
    		 2
    		 5
    		 1
    		 3
    Nervous system disorders
    Headache
    		 24
    		 60
    		 1
    		 3
    Insomnia
    		 17
    		 43
    		 1
    		 3
    Paresthesia
    		 13
    		 33
    		 2
    		 5
    Dizziness (excluding vertigo)
    		 9
    		 23
    Tremor
    		 5
    		 13
    Convulsion
    		 3
    		 8
    		 2
    		 5
    Somnolence
    		 3
    		 8
    Coma
    		 2
    		 5
    		 2
    		 5
    Cardiac disorders
    Tachycardia
    		 22
    		 55
    ECG QT corrected interval prolonged > 500 msec
    		 16
    		 40
    Palpitations
    		 4
    		 10
    ECG abnormal other than QT interval prolongation
    		 3
    		 8
    Metabolism and nutrition disorders
    Hypokalemia
    		 20
    		 50
    		 5
    		 13
    Hypomagnesemia
    		 18
    		 45
    		 5
    		 13
    Hyperglycemia
    		 18
    		 45
    		 5
    		 13
    ALT increased
    		 8
    		 20
    		 2
    		 5
    Hyperkalemia
    		 7
    		 18
    		 2
    		 5
    AST increased
    		 5
    		 13
    		 1
    		 3
    Hypocalcemia
    		 4
    		 10
    Hypoglycemia
    		 3
    		 8
    Acidosis
    		 2
    		 5
    Hematologic disorders
    Leukocytosis
    		 20
    		 50
    		 1
    		 3
    Anemia
    		 8
    		 20
    		 2
    		 5
    Thrombocytopenia
    		 7
    		 18
    		 5
    		 13
    Febrile neutropenia
    		 5
    		 13
    		 3
    		 8
    Neutropenia
    		 4
    		 10
    		 4
    		 10
    Disseminated intravascular coagulation
    		 3
    		 8
    		 3
    		 8
    Lymphadenopathy
    		 3
    		 8
    Skin and subcutaneous tissue disorders
    Dermatitis
    		 17
    		 43
    Pruritus
    		 13
    		 33
    		 1
    		 3
    Ecchymosis
    		 8
    		 20
    Dry skin
    		 6
    		 15
    Erythema - non-specific
    		 5
    		 13
    Increased sweating
    		 5
    		 13
    Facial edema
    		 3
    		 8
    Night sweats
    		 3
    		 8
    Petechiae
    		 3
    		 8
    Hyperpigmentation
    		 3
    		 8
    Non-specific skin lesions
    		 3
    		 8
    Urticaria
    		 3
    		 8
    Local exfoliation
    		 2
    		 5
    Eyelid edema
    		 2
    		 5
    Musculoskeletal, connective tis sue, and bone disorders
    Arthralgia
    		 13
    		 33
    		 3
    		 8
    Myalgia
    		 10
    		 25
    		 2
    		 5
    Bone pain
    		 9
    		 23
    		 4
    		 10
    Back pain
    		 7
    		 18
    		 1
    		 3
    Neck pain
    		 5
    		 13
    Pain in limb
    		 5
    		 13
    		 2
    		 5
    Psychiatric disorders
    Anxiety
    		 12
    		 30
    Depression
    		 8
    		 20
    Agitation
    		 2
    		 5
    Confusion
    		 2
    		 5
    Vascular disorders
    Hypotension
    		 10
    		 25
    		 2
    		 5
    Flushing
    		 4
    		 10
    Hypertension
    		 4
    		 10
    Pallor
    		 4
    		 10
    Infections and infestations
    Sinusitis
    		 8
    		 20
    Herpes simplex
    		 5
    		 13
    Upper respiratory tract infection
    		 5
    		 13
    		 1
    		 3
    Bacterial infection - non-specific
    		 3
    		 8
    		 1
    		 3
    Herpes zoster
    		 3
    		 8
    Nasopharyngitis
    		 2
    		 5
    Oral candidiasis
    		 2
    		 5
    Sepsis
    		 2
    		 5
    		 2
    		 5
    Reproductive system disorders
    Vaginal hemorrhage
    		 5
    		 13
    Intermenstrual bleeding
    		 3
    		 8
    Ocular disorders
    Eye irritation
    		 4
    		 10
    Blurred vision
    		 4
    		 10
    Dry eye
    		 3
    		 8
    Painful red eye
    		 2
    		 5
    Renal and urinary disorders
    Renal failure
    		 3
    		 8
    		 1
    		 3
    Renal impairment
    		 3
    		 8
    Oliguria
    		 2
    		 5
    Incontinence
    		 2
    		 5
    Ear disorders
    Earache
    		 3
    		 8
    Tinnitus
    		 2
    		 5

    Other Clinically Relevant Adverse Reactions 

    Leukocytosis

    Arsenic trioxide can induce proliferation of leukemic promyelocytes resulting in a rapid increase in white blood cell count. Leukocytosis greater than 10 Gi/L developed during induction therapy in 50% of patients receiving arsenic trioxide monotherapy for relapsed/refractory APL. In the relapsed/refractory setting, a relationship did not exist between baseline WBC counts and development of hyperleukocytosis nor baseline WBC counts and peak WBC counts.

    6.2 Postmarketing Experience

    The following adverse reactions have been identified during postapproval use of arsenic trioxide. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate the frequency or establish a causal relationship to drug exposure.

    Cardiac disorders: Ventricular extrasystoles in association with QT prolongation, ventricular tachycardia in association with QT prolongation, including torsade de pointes, atrioventricular block, and congestive heart failure

    Ear and labyrinth disorders: Deafness

    Hematologic disorders: Pancytopenia, bone marrow necrosis

    Infections:  Herpes zoster

    Investigations: Gamma-glutamyltransferase increased

    Musculoskeletal and connective tissue disorders: Bone pain, myalgia, rhabdomyolysis

    Neoplasms benign, malignant and unspecified: Melanoma, pancreatic cancer, squamous cell carcinoma

    Nervous system disorders: Peripheral neuropathy, paresis, seizures, confusion, encephalopathy, Wernicke's encephalopathy, posterior reversible encephalopathy syndrome

    Skin and subcutaneous tissue disorders: Toxic epidermal necrolysis

  • 7 DRUG INTERACTIONS

    Drugs That Can Prolong the QT/QTc Interval

    Concomitant use of these drugs and arsenic trioxide may increase the risk of serious QT/QTc interval prolongation [see Warnings and Precautions (5.1)]. Discontinue or replace with an alternative drug that does not prolong the QT/QTc interval while the patient is using arsenic trioxide. Monitor ECGs more frequently in patients when it is not feasible to avoid concomitant use.

    Drugs That Can Lead to Electrolyte Abnormalities

    Electrolyte abnormalities increase the risk of serious QT/QTc interval prolongation [see Warnings and Precautions (5.1)]. Avoid concomitant use of drugs that can lead to electrolyte abnormalities. Monitor electrolytes more frequently in patients who must receive concomitant use of these drugs and arsenic trioxide.

    Drugs That Can Lead to Hepatotoxicity

    Use of these drugs and arsenic trioxide may increase the risk of serious hepatotoxicity [see Warnings and Precautions (5.4)]. Discontinue or replace with an alternative drug that does not cause hepatotoxicity while the patient is using arsenic trioxide. Monitor liver function tests more frequently in patients when it is not feasible to avoid concomitant use.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Risk Summary

    Based on the mechanism of action [see Clinical Pharmacology (12.1)] and findings in animal studies, arsenic trioxide can cause fetal harm when administered to a pregnant woman. Arsenic trioxide was embryolethal and teratogenic in rats when administered on gestation day 9 at a dose approximately 10 times the recommended human daily dose on a mg/m2 basis (see Data). A related trivalent arsenic, sodium arsenite, produced teratogenicity when administered during gestation in mice at a dose approximately 5 times the projected human dose on a mg/m2basis and in hamsters at an intravenous dose approximately equivalent to the projected human daily dose on a mg/m2 basis. There are no studies with the use of arsenic trioxide in pregnant women, and limited published data on arsenic trioxide use during pregnancy are insufficient to inform a drug-associated risk of major birth defects and miscarriage. Advise pregnant women of the potential risk to a fetus.

    The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

    Data

    Human Data

    One patient was reported to deliver a live infant with no reported congenital anomalies after receiving arsenic trioxide during the first five months of pregnancy. A second patient became pregnant three months after discontinuing arsenic trioxide and was reported to have a normal pregnancy outcome. A third patient was a pregnant healthcare provider who experienced dermal contact with liquid arsenic trioxide and had a normal pregnancy outcome after treatment and monitoring. A fourth patient who became pregnant while receiving arsenic trioxide had a miscarriage.

    Animal Data

    Studies in pregnant mice, rats, hamsters, and primates have shown that inorganic arsenicals cross the placental barrier when given orally or by injection. An increase in resorptions, neural-tube defects, anophthalmia and microphthalmia were observed in rats administered 10 mg/kg of arsenic trioxide on gestation day 9 (approximately 10 times the recommended human daily dose on a mg/m  basis). Similar findings occurred in mice administered a 10 mg/kg dose of a related trivalent arsenic, sodium arsenite (approximately 5 times the projected human dose on a mg/m2 basis), on gestation days 6, 7, 8, or 9. Intravenous injection of 2 mg/kg sodium arsenite (approximately equivalent to the projected human daily dose on a mg/m2 basis) on gestation day 7 (the lowest dose tested) resulted in neural-tube defects in hamsters.

    8.2 Lactation

    Risk Summary

    Arsenic trioxide is excreted in human milk. There are no data on the effects of arsenic trioxide on the breastfed child or on milk production. Because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with arsenic trioxide and for 2 weeks after the final dose.

    8.3 Females and Males of Reproductive Potential

    Arsenic trioxide can cause fetal harm when administered to a pregnant woman [see Use in Specific Populations (8.1)].

    Pregnancy Testing

    Conduct pregnancy testing in females of reproductive potential prior to initiation of arsenic trioxide.

    Contraception 

    Females

    Advise females of reproductive potential to use effective contraception during treatment with arsenic trioxide and for 6 months after the final dose.

    Males

    Advise males with female partners of reproductive potential to use effective contraception during treatment with arsenic trioxide and for 3 months after the final dose.

    Infertility

    Males

    Based on testicular toxicities including decreased testicular weight and impaired spermatogenesis observed in animal studies, arsenic trioxide may impair fertility in males of reproductive potential [see Nonclinical Toxicology (13.1)].

    8.4 Pediatric Use

    The safety and efficacy of arsenic trioxide as a single agent for treatment of pediatric patients with relapsed or refractory APL is supported by the pivotal phase 2 study in 40 patients with relapsed or refractory APL. Five patients below the age of 18 years (age range: 5 to 16 years) were treated with arsenic trioxide at the recommended dose of 0.15 mg/kg/day. A literature review included an additional 17 patients treated with arsenic trioxide for relapsed or refractory APL, with ages ranging from 4 to 21 years. No differences in efficacy and safety were observed by age.

    8.5 Geriatric Use

    Use of arsenic trioxide as monotherapy in patients with relapsed or refractory APL is supported by the open-label, single-arm trial that included 6 patients aged 65 and older (range: 65 to 73 years). A literature review included an additional 4 patients aged 69 to 72 years who were treated with arsenic trioxide for relapsed or refractory APL. No overall differences in safety or effectiveness were observed between these patients and younger patients.

    8.6 Renal Impairment

    Exposure of arsenic trioxide may be higher in patients with severe renal impairment [see Clinical Pharmacology (12.3)]. Monitor patients with severe renal impairment (creatinine clearance [CLcr] less than 30 mL/min) frequently for toxicity; a dose reduction may be warranted.

    The use of arsenic trioxide in patients on dialysis has not been studied.

    8.7 Hepatic Impairment

    Since limited data are available across all hepatic impairment groups, caution is advised in the use of arsenic trioxide in patients with hepatic impairment [see Clinical Pharmacology (12.3)]. Monitor patients with severe hepatic impairment (Child-Pugh Class C) frequently for toxicity.

  • 10 OVERDOSAGE

    Manifestations

    Manifestations of arsenic trioxide overdosage include convulsions, muscle weakness, and confusion.

    Management

    For symptoms of arsenic trioxide overdosage, immediately discontinue arsenic trioxide and consider chelation therapy.

    A conventional protocol for acute arsenic intoxication includes dimercaprol administered at a dose of 3 mg/kg intramuscularly every 4 hours until immediate life-threatening toxicity has subsided. Thereafter, penicillamine at a dose of 250 mg orally, up to a maximum frequency of four times per day (≤ 1 g per day), may be given.

  • 11 DESCRIPTION

    Arsenic trioxide injection is a sterile injectable solution of arsenic trioxide. The molecular formula of arsenic trioxide in the solid state is As2O3, with a molecular weight of 197.84 g/mol and the following structural formula:

    Image

    Arsenic trioxide is a white to off-white powder. It is practically insoluble to sparingly soluble in water. It dissolves in solutions of alkali hydroxides (NaOH 1 M). It is practically insoluble in ethanol, chloroform and ethyl ether.

    Arsenic trioxide injection is available in 10 mL single-dose vials containing 10 mg or 12 mg of arsenic trioxide. Arsenic trioxide injection is formulated as a sterile, nonpyrogenic, clear solution of arsenic trioxide in water for injection using sodium hydroxide and dilute hydrochloric acid to adjust to pH 8. Arsenic trioxide injection is preservative-free. Arsenic trioxide, the active ingredient, is present at a concentration of 1 mg/mL and 2 mg/mL. Inactive ingredients and their respective approximate concentrations are sodium hydroxide (1.2 mg/mL) for solubilization, and sodium hydroxide and hydrochloric acid for pH adjustment to pH 8.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    The mechanism of action of arsenic trioxide is not completely understood. Arsenic trioxide causes morphological changes and DNA fragmentation characteristic of apoptosis in NB4 human promyelocytic leukemia cells in vitro. Arsenic trioxide also causes damage or degradation of the fusion protein promyelocytic leukemia (PML)-retinoic acid receptor (RAR)-alpha.

    12.2 Pharmacodynamics

    Cardiac Electrophysiology

    In a single-arm trial of arsenic trioxide (0.15 mg/kg daily), 16 of 40 patients (40%) had a QTc interval greater than 500 msec. Prolongation of the QTc was observed between 1 and 5 weeks after arsenic trioxide infusion, and then returned towards baseline by the end of 8 weeks after arsenic trioxide infusion.

    12.3 Pharmacokinetics

    The inorganic, lyophilized form of arsenic trioxide, when placed into solution, immediately forms the hydrolysis product arsenious acid (AsIII). AsIII is the pharmacologically active species of arsenic trioxide. Monomethylarsonic acid (MMAV), and dimethylarsinic acid (DMAV) are the main pentavalent metabolites formed during metabolism, in addition to arsenic acid (AsV) a product of AsIII oxidation.

    The pharmacokinetics of arsenical species ([AsIII], [AsV], [MMAV], [DMAV]) were determined in 6 APL patients following once-daily doses of 0.15 mg/kg for 5 days per week. Over the total single-dose range of 7 mg to 32 mg (administered as 0.15 mg/kg), systemic exposure (AUC) appears to be linear.

    Peak plasma concentrations of arsenious acid (AsIII), the primary active arsenical species were reached at the end of infusion (2 hours). Plasma concentration of AsIII declined in a biphasic manner with a mean elimination half-life of 10 to 14 hours and is characterized by an initial rapid distribution phase followed by a slower terminal elimination phase. The daily exposure to AsIII (mean AUC0-24h) was 194 ng∙hr/mL (n=5) on Day 1 of Cycle 1 and 332 ng∙hr/mL (n=6) on Day 25 of Cycle 1, which represents an approximate 2-fold accumulation.

    The primary pentavalent metabolites, MMAV and DMAV, are slow to appear in plasma (approximately 10 to 24 hours after first administration of arsenic trioxide), but, due to their longer half-life, accumulate more upon multiple dosing than does AsIII. The mean estimated terminal elimination half-lives of the metabolites MMAV and DMAV are 32 hours and 72 hours, respectively. Approximate accumulation ranged from 1.4- to 8-fold following multiple dosing as compared to single-dose administration. AsV is present in plasma only at relatively low levels.

    Distribution

    The volume of distribution (Vss) for AsIII is large (mean 562 L, N=10) indicating that AsIII is widely distributed throughout body tissues. Vss is also dependent on body weight and increases as body weight increases.

    Elimination

    Metabolism

    Much of the AsIII is distributed to the tissues where it is methylated to the less cytotoxic metabolites, monomethylarsonic acid (MMAV) and dimethylarsinic acid (DMAV) by methyltransferases primarily in the liver. The metabolism of arsenic trioxide also involves oxidation of AsIII to AsV, which may occur in numerous tissues via enzymatic or nonenzymatic processes. AsV is present in plasma only at relatively low levels following administration of arsenic trioxide.

    Excretion

    Approximately 15% of the administered arsenic trioxide dose is excreted in the urine as unchanged AsIII. The methylated metabolites of AsIII (MMAV, DMAV) are primarily excreted in the urine. The total clearance of AsIII is 49 L/h and the renal clearance is 9 L/h. Clearance is not dependent on body weight or dose administered over the range of 7 mg to 32 mg.

    Specific Populations

    Patients with Renal Impairment

    The effect of renal impairment on the pharmacokinetics of AsIII, AsV, and the pentavalent metabolites MMAV and DMAV was evaluated in 20 patients with advanced malignancies. Patients were classified as having normal renal function (creatinine clearance [CLcr] > 80 mL/min, n=6), mild renal impairment (CLcr 50 to 80 mL/min, n=5), moderate renal impairment (CLcr 30 to 49 mL/min, n=6), or severe renal impairment (CLcr < 30 mL/min, n=3). Following twice-weekly administration of 0.15 mg/kg over a 2-hour infusion, the mean AUC0-INF for AsIII was comparable among the normal, mild and moderate renal impairment groups. However, in the severe renal impairment group, the mean AUC0-INF for AsIII was approximately 48% higher than that in the normal group.

    Systemic exposure to MMAV and DMAV tended to be larger in patients with renal impairment; however, the clinical consequences of this increased exposure are not known. AsV plasma levels were generally below the limit of assay quantitation in patients with impaired renal function [see Use in Specific Populations (8.6)]. The use of arsenic trioxide in patients on dialysis has not been studied.

    Patients with Hepatic Impairment

    The effect of pharmacokinetics of AsIII, AsV, and the pentavalent metabolites MMAV and DMAVwas evaluated following administration of 0.25 to 0.50 mg/kg of arsenic trioxide in patients with hepatocellular carcinoma. Patients were classified as having normal hepatic function (n=4), mild hepatic impairment (Child-Pugh class A, n=12), moderate hepatic impairment (Child-Pugh class B, n=3), or severe hepatic impairment (Child-Pugh class C, n=1). No clear trend toward an increase in systemic exposure to AsIII, AsV, MMAV or DMAV was observed with decreasing level of hepatic function as assessed by dose-normalized (per mg dose) AUC in the mild and moderate hepatic impairment groups. However, the one patient with severe hepatic impairment had mean dose-normalized AUC0-24h and Cmax values 40% and 70% higher, respectively, than those patients with normal hepatic function. The mean dose-normalized trough plasma levels for both MMAV and DMAVin this severely hepatically impaired patient were 2.2-fold and 4.7-fold higher, respectively, than those in the patients with normal hepatic function [see Use in Specific Populations (8.7)].

    Pediatric Patients

    Following intravenous administration of 0.15 mg/kg/day of arsenic trioxide in 10 APL patients (median age = 13.5 years, range 4 to 20 years), the daily exposure to AsIII (mean AUC0-24h) was 317 ng∙hr/mL on Day 1 of Cycle 1 [see Use in Specific Populations (8.4)].

    Drug Interaction Studies

    No formal assessments of pharmacokinetic drug-drug interactions between arsenic trioxide and other drugs have been conducted. The methyltransferases responsible for metabolizing arsenic trioxide are not members of the cytochrome P450 family of isoenzymes. In vitro incubation of arsenic trioxide with human liver microsomes showed no inhibitory activity on substrates of the major cytochrome P450 (CYP) enzymes such as 1A2, 2A6, 2B6, 2C8, 2C9, 2C19, 2D6, 2E1, 3A4/5, and 4A9/11. The pharmacokinetics of drugs that are substrates for these CYP enzymes are not expected to be affected by concomitant treatment with arsenic trioxide.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility

    Carcinogenicity studies have not been conducted with arsenic trioxide [see Warnings and Precautions (5.6)].

    Arsenic trioxide and trivalent arsenite salts have not been demonstrated to be mutagenic to bacteria, yeast, or mammalian cells. Arsenite salts are clastogenic in vitro (human fibroblast, human lymphocytes, Chinese hamster ovary cells, Chinese hamster V79 lung cells). Trivalent arsenic was genotoxic in the chromosome aberrations assay and micronucleus bone marrow assay in mice.

    The effect of arsenic on fertility has not been adequately studied in humans. Decreased testicular weight and impaired spermatogenesis have been reported in animal studies. Male Wistar rat pups were administered 1.5 mg/kg sodium arsenite solution via the intraperitoneal route from postnatal days 1 to 14 and testes were collected for evaluation on postnatal days 15, 21, and 50. Results of this study revealed an altered morphology of the seminiferous tubules along with degeneration of spermatogenic cells, increased number of sperm with abnormal morphology, and decreased sperm counts. In beagle dogs administered intravenous arsenic trioxide for 90 days, reduced inner cell layers within seminiferous tubules and significantly decreased numbers of spermatocytes, spermatozoa, and sperm cells were observed at doses of 1 mg/kg/day and higher. The 1 mg/kg/day dose is approximately 3 times the recommended human daily dose on a mg/m2 basis.

  • 14 CLINICAL STUDIES

    14.2 Relapsed or Refractory APL

    Arsenic trioxide was investigated in Study PLRXAS01, an open-label, single-arm trial in 40 patients with relapsed or refractory APL who were previously treated with an anthracycline and a retinoid regimen. Patients received arsenic trioxide 0.15 mg/kg/day intravenously over 1 to 2 hours until the bone marrow was cleared of leukemic cells or for a maximum of 60 days. The CR (absence of visible leukemic cells in bone marrow and peripheral recovery of platelets and white blood cells with a confirmatory bone marrow ≥ 30 days later) rate in this population of previously treated patients was 28 of 40 (70%). Among the 22 patients who had relapsed less than one year after treatment with tretinoin, there were 18 complete responders (82%). Of the 18 patients receiving arsenic trioxide ≥ one year from tretinoin treatment, there were 10 complete responders (55%). The median time to bone marrow remission was 44 days and to onset of CR was 53 days. Three of 5 children, 5 years or older, achieved CR. No children less than 5 years old were treated.

    Three to six weeks following bone marrow remission, 31 patients received consolidation therapy with arsenic trioxide, at the same dose, for 25 additional days over a period up to 5 weeks. In follow-up treatment, 18 patients received further arsenic trioxide as a maintenance course. Fifteen patients had bone marrow transplants. At last follow-up, 27 of 40 patients were alive with a median follow-up time of 484 days (range 280 to 755) and 23 of 40 patients remained in complete response with a median follow-up time of 483 days (range 280 to 755).

    Cytogenetic conversion to no detection of the APL chromosome rearrangement was observed in 24 of 28 (86%) patients who met the response criteria defined above, in 5 of 5 (100%) patients who met some, but not all, of the response criteria, and 3 of 7 (43%) of patients who did not respond. RT-PCR conversions to no detection of the APL gene rearrangement were demonstrated in 22 of 28 (79%) of patients who met the response criteria, in 3 of 5 (60%) of patients who met some, but not all, of the response criteria, and in 2 of 7 (29%) of patients who did not respond.

    Responses were seen across all age groups tested, ranging from 6 to 72 years. The ability to achieve a CR was similar for both sexes. There were insufficient patients of Black, Hispanic, or Asian ancestry to estimate relative response rates in these groups, but responses were seen in each group.

  • 15 REFERENCES

    1. "OSHA Hazardous Drugs." OSHA. http://www.osha.gov/SLTC/hazardousdrugs/index.html
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    How Supplied

    Arsenic trioxide injection is supplied as a sterile, clear, colorless solution in glass, single-dose vials.

    It is available as follows:

    10 mg/10 mL (1 mg/mL):
    10 mL Single-Dose Vial (10 mL fill):
    		 NDC: 81607-005-10
    10 Single-Dose Vials in 1 Carton:
    		 NDC: 81607-005-11
    12 mg/6 mL (2 mg/mL):
    10 mL Single-Dose Vial (6 mL fill):
    		 NDC: 81607-006-06
    10 Single-Dose Vials in 1 Carton:
    		 NDC: 81607-006-07

    Storage and Handling

    Store at 20° to 25°C (68° to 77°F); excursions permitted between 15° to 30°C (59° to 86°F) [see USP Controlled Room Temperature]. Do not freeze.

    Arsenic trioxide injection is a hazardous drug. Follow applicable special handling and disposal procedures.1

  • 17 PATIENT COUNSELING INFORMATION

    Differentiation Syndrome

    Advise patients that symptoms of APL differentiation syndrome include fever, sudden weight gain, dizziness/lightheadedness, labored breathing, and accumulation of fluid in the lungs, heart, and chest. This syndrome is managed by immediate treatment with high-dose corticosteroids. Advise patients to immediately report any of these symptoms [see Warnings and Precautions (5.1)].

    Cardiac Conduction Abnormalities

    Advise patients that arsenic trioxide may cause ECG abnormalities, including QT prolongation. If extreme, this prolongation has the potential to cause fainting, irregular heartbeat, or more serious side effects. Advise patients to immediately report any of these symptoms. Advise patients to provide a complete list of current medications as caution should be taken when arsenic trioxide is co-administered with other medications that can cause QT prolongation or lead to electrolyte abnormalities [see Warnings and Precautions (5.2) and Drug Interactions (7)].

    Encephalopathy and Wernicke's Encephalopathy (WE)

    Advise patients that symptoms of encephalopathies include neurological symptoms such as confusion, decreased level of consciousness, seizures, cognitive deficits, ataxia, visual symptoms and ocular motor dysfunction. Advise patients and caregivers to closely monitor for neurological symptoms and immediately report them to their healthcare provider [see Warnings and Precautions (5.3)].

    Advise patients at risk for thiamine deficiency (e.g., chronic alcohol use, malabsorption, nutritional deficiency, concomitant use of furosemide) that Wernicke's encephalopathy is a neurologic emergency that can be prevented and treated with thiamine supplementation, and to immediately report any neurological symptoms to their healthcare provider [see Warnings and Precautions (5.3)].

    Embryo-Fetal Toxicity 

    Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to inform their healthcare provider of a known or suspected pregnancy [see Warnings and Precautions (5.5) and Use in Specific Populations 8.1)].

    Advise females of reproductive potential to use effective contraception during treatment with arsenic trioxide and for 6 months after the last dose [see Use in Specific Populations (8.3)].

    Advise males with female partners of reproductive potential to use effective contraception during treatment with arsenic trioxide for 3 months after the last dose [see Use in Specific Populations (8.3)].

    Lactation 

    Advise women not to breastfeed during treatment with arsenic trioxide and for 2 weeks after the last dose [see Use in Specific Populations (8.2)].

    Infertility 

    Advise males of reproductive potential that arsenic trioxide may impair fertility [see Use in Specific Population (8.3)].

    Other Adverse Reactions

    Advise patients of the expected adverse reactions of arsenic trioxide. Most patients in clinical trials experienced some drug-related toxicity, most commonly leukocytosis, gastrointestinal symptoms (nausea, vomiting, diarrhea, and abdominal pain), fatigue, edema, hyperglycemia, dyspnea, cough, rash or itching, headaches, and dizziness. Advise patients to call their healthcare provider at the onset of any adverse reactions [see Adverse Reactions (6.1)].

  • SPL UNCLASSIFIED SECTION

    Manufactured by:

    MSN Laboratories Private Limited 

    Telangana - 509 228, INDIA.

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL - Arsenic Trioxide Injection, 10 mg/10 mL (1 mg/mL)

    Rx Only

    NDC: 81607-005-11

    Arsenic Trioxide Injection

    10 mg/10 mL

    (1 mg/mL)

    For Intravenous Use Only

    Caution: Cytotoxic Agent

    Discard Unused Portion

    10 x 10 mL Single-Dose Vials

    Orbicular

    Carton label 1 mg
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL - Arsenic Trioxide Injection, 10 mg/10 mL (1 mg/mL)

    Rx Only

    NDC: 81607-005-10

    Arsenic Trioxide Injection

    10 mg/10 mL

    (1 mg/mL)

    For Intravenous Use Only

    Caution: Cytotoxic Agent

    Discard Unused Portion

    10 mL Single-Dose Vial

    Orbicular

    Container label 1 mg
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL - Arsenic Trioxide Injection, 12 mg/6 mL (2 mg/mL)

    Rx Only

    NDC: 81607-006-07

    Arsenic Trioxide Injection

    12 mg/6 mL

    (2 mg/mL)

    For Intravenous Use Only

    Caution: Cytotoxic Agent

    Single-Dose Vial - Discard Unused Portion

    10 x 6 mL Single-Dose Vials

    Orbicular

    Carton label 2 mg
  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    PACKAGE LABEL - Arsenic Trioxide Injection, 12 mg/6 mL (2 mg/mL)

    Rx Only

    NDC: 81607-006-06

    Arsenic Trioxide Injection

    12 mg/6 mL

    (2 mg/mL)

    For Intravenous Use Only

    Caution: Cytotoxic Agent

    Single-Dose Vial

    Discard Unused Portion

    6 mL

    Orbicular

    Container label 2 mg
  • INGREDIENTS AND APPEARANCE
    ARSENIC TRIOXIDE 
    arsenic trioxide injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 81607-005
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    ARSENIC TRIOXIDE (UNII: S7V92P67HO) (ARSENIC CATION (3+) - UNII:C96613F5AV) ARSENIC TRIOXIDE1 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 81607-005-1110 in 1 CARTON05/31/2023
    1NDC: 81607-005-1010 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21741305/31/2023
    ARSENIC TRIOXIDE 
    arsenic trioxide injection, solution
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 81607-006
    Route of AdministrationINTRAVENOUS
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    ARSENIC TRIOXIDE (UNII: S7V92P67HO) (ARSENIC CATION (3+) - UNII:C96613F5AV) ARSENIC TRIOXIDE2 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    HYDROCHLORIC ACID (UNII: QTT17582CB)  
    WATER (UNII: 059QF0KO0R)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 81607-006-0710 in 1 CARTON05/31/2023
    1NDC: 81607-006-066 mL in 1 VIAL, SINGLE-DOSE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21741305/31/2023
    Labeler - Orbicular Pharmaceutical Technologies Private Limited (858874366)
    Establishment
    NameAddressID/FEIBusiness Operations
    MSN Laboratories Private Limited650786952ANALYSIS(81607-005, 81607-006) , MANUFACTURE(81607-005, 81607-006)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.